netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Rivaroxaban found 19 matches

Formulary items 2 matches
   
Open monograph to display formulary status BNF Category
  Rivaroxaban  (Xarelto®) Cardiovascular system - Oral anticoagulants - 02.08.02
  Rivaroxaban with aspirin Cardiovascular system - Oral anticoagulants - 02.08.02
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section LSCMMG: Rivaroxaban 10mg tablets (02.08.02)
link in drug section LSCMMG: Rivaroxaban with aspirin (02.08.02)
link in drug section MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban (01.02)
link in drug section MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban (05.01.05)
link in drug section MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban (05.01.05)
link in subsection MHRA: New oral anticoagulants apixaban (Eliquis▼), dabigatran (Pradaxa) and rivaroxaban (Xarelto▼) (02.08.02)
link in drug section MHRA: Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial (02.08.02)
link in drug section MHRA: Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial (02.08.02)
link in drug section MHRA: Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food (02.08.02)
link in drug section MHRA: Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food (02.08.02)
link in drug section NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (02.08.02)
link in drug section NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (02.08.02)
link in drug section NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (02.08.02)
link in drug section NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (02.08.02)
link in drug section NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (02.08.02)
link in drug section NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (02.08.02)
link in drug section NICE TA697- Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (02.08.02)


 
netFormulary